Squarepoint Ops LLC Acquires Shares of 380,927 Caris Life Sciences, Inc. $CAI

Squarepoint Ops LLC bought a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 380,927 shares of the company’s stock, valued at approximately $6,788,000. Squarepoint Ops LLC owned about 0.13% of Caris Life Sciences as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Global Retirement Partners LLC grew its stake in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after buying an additional 999 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Caris Life Sciences by 839.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after acquiring an additional 1,469 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the period. Fifth Third Bancorp acquired a new position in shares of Caris Life Sciences in the first quarter valued at approximately $31,000. Finally, Sterling Capital Management LLC grew its position in shares of Caris Life Sciences by 128.3% in the first quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after purchasing an additional 1,083 shares during the last quarter.

Caris Life Sciences Trading Up 0.0%

Shares of NASDAQ:CAI opened at $24.04 on Friday. The business’s 50 day simple moving average is $20.47 and its 200 day simple moving average is $18.95. Caris Life Sciences, Inc. has a 1 year low of $14.19 and a 1 year high of $35.20. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. The company has a market capitalization of $6.79 billion, a P/E ratio of 66.78 and a beta of 1.10.

Caris Life Sciences announced that its Board of Directors has initiated a share repurchase program on Monday, June 8th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 2.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Caris Life Sciences

In other news, President David Spetzler sold 119,212 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.76, for a total transaction of $2,951,689.12. Following the sale, the president directly owned 1,182,871 shares of the company’s stock, valued at approximately $29,287,885.96. This represents a 9.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 50.00% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on CAI shares. Wolfe Research cut Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. BTIG Research upped their price objective on Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. UBS Group started coverage on Caris Life Sciences in a report on Wednesday. They set a “neutral” rating and a $28.00 target price for the company. Evercore reissued an “outperform” rating and issued a $26.00 target price on shares of Caris Life Sciences in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $26.50.

Caris Life Sciences Profile

Caris Life Sciences is a precision medicine and biotechnology company headquartered in Irving, Texas. Founded in 2008, the company combines molecular profiling, artificial intelligence and clinical data to support more informed decisions in cancer diagnosis and treatment.

Caris provides comprehensive tumor profiling and other laboratory testing services designed to identify genetic, molecular and immune characteristics of a patient’s cancer. Its offerings are intended to help physicians match patients with targeted therapies, immunotherapies and clinical trials, while also supporting cancer research and drug development.

The company serves healthcare providers, biopharmaceutical companies and academic or research institutions.